A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study

被引:60
作者
Durez, P
Van den Bosch, F
Corluy, L
Veys, EM
De Clerck, L
Peretz, A
Malaise, M
Devogelaer, JP
Vastesaeger, N
Geldhof, A
Westhovens, R
机构
[1] Catholic Univ Louvain, Clin Univ St Luc, Dept Rheumatol, Louvain, Belgium
[2] Univ Hosp RU Ghent, Dept Rheumatol, Ghent, Belgium
[3] Univ Hosp KU Leuven, Dept Rheumatol, Louvain, Belgium
[4] Univ Antwerp, Univ Antwerp Hosp, Dept Rheumatol, Antwerp, Belgium
[5] Univ Hosp Brugmann, Dept Rheumatol, Brussels, Belgium
[6] Univ Hosp Liege, Dept Rheumatol, Liege, Belgium
[7] Centocor BV, Leiden, Netherlands
关键词
rheumatoid arthritis; infliximab; dose adjustment; ACR core set;
D O I
10.1093/rheumatology/keh494
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients suffering from active refractory RA despite methotrexate, were treated with i.v. infusions of infliximab (3 mg/kg) on week 0, 2, 6 and every 8 weeks thereafter. Based on the clinical judgement at week 22, patients received a dose increase of 100 mg from week 30 on. The American College of Rheumatology (ACR) core set for disease activity measures was regularly assessed. Results. Five hundred and eleven RA patients were included. At week 22, 61.4, 34 and 14.1% of all patients met ACR 20, ACR 50 and ACR 70 criteria, respectively, and 6.1% of patients were in remission. A low swollen joint count at baseline was correlated with improvement at week 22 for ACR 20 (P < 0.06), ACR 50 (P < 0.06) and ACR 70 (P < 0.005). The change in HAQ score between weeks 0 and 22 was predictive for response at week 54 (P < 0.01). The dose of infliximab was increased by 100 mg in 22% of the patients. Most baseline values of patients requiring dose increase were higher (P <= 0.001) than the baseline values of the remaining patients. Increasing the dose of infliximab by one vial from week 30 on could circumvent the partial loss of response in these patients. Conclusion. Infliximab use in this large out-patient cohort resulted in a significant clinical improvement. A subgroup that partially lost response during the first 22 weeks could regain response by adding 100 mg of infliximab to the subsequent doses. Due to the current study design, however, a regression to the mean like effect could not be ruled out.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 14 条
  • [1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [2] The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    Clair, EWS
    Wagner, CL
    Fasanmade, AA
    Wang, B
    Schaible, T
    Kavanaugh, A
    Keystone, EC
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (06): : 1451 - 1459
  • [3] AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS
    FELSON, DT
    ANDERSON, JJ
    BOERS, M
    BOMBARDIER, C
    FURST, D
    GOLDSMITH, C
    KATZ, LM
    LIGHTFOOT, R
    PAULUS, H
    STRAND, V
    TUGWELL, P
    WEINBLATT, M
    WILLIAMS, HJ
    WOLFE, F
    KIESZAK, S
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (06): : 727 - 735
  • [4] Are better endpoints and better design of clinical trials needed?
    Fransen, J
    van Riel, PLCM
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (01): : 97 - 109
  • [5] Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
    Gardam, MA
    Keystone, EC
    Menzies, R
    Manners, S
    Skamene, E
    Long, R
    Vinh, DC
    [J]. LANCET INFECTIOUS DISEASES, 2003, 3 (03) : 148 - 155
  • [6] Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report
    Gómez-Reino, JJ
    Carmona, L
    Valverde, VR
    Mola, EM
    Montero, MD
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (08): : 2122 - 2127
  • [7] Harley CR, 2003, AM J MANAG CARE, V9, pS136
  • [8] Keystone EC, 2003, ANN RHEUM DIS, V62, P34
  • [9] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial
    Maini, R
    St Clair, EW
    Breedveld, F
    Furst, D
    Kalden, J
    Weisman, M
    Smolen, J
    Emery, P
    Harriman, G
    Feldmann, M
    Lipsky, P
    [J]. LANCET, 1999, 354 (9194) : 1932 - 1939
  • [10] MODIFIED DISEASE-ACTIVITY SCORES THAT INCLUDE 28-JOINT COUNTS - DEVELOPMENT AND VALIDATION IN A PROSPECTIVE LONGITUDINAL-STUDY OF PATIENTS WITH RHEUMATOID-ARTHRITIS
    PREVOO, MLL
    VANTHOF, MA
    KUPER, HH
    VANLEEUWEN, MA
    VANDEPUTTE, LBA
    VANRIEL, PLCM
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (01): : 44 - 48